Full Press Release Details
Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
patent coverage for both composition of matter & specific receptor ligands for the treatment of erectile dysfunction
TIKVA, Israel, November 9, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a
pipeline of proprietary small molecule drugs being developed to treat inflammatory and liver diseases, cancer, and sexual dysfunction,
today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering
A3 adenosine receptor ligands for use in the treatment of erectile dysfunction. The patent addresses methods for treating erectile
dysfunction with different A3 adenosine receptor (A3AR) ligands including Can-Fite's erectile dysfunction drug candidate,
CF602. This marks Can-Fite's second notice of allowance in the U.S. for ligands which bind to the A3AR target. The prior
patent, issued in February, addresses composition of matter for allosteric compounds. Can-Fite's CF602, an allosteric compound
at the A3AR demonstrated effects on erection superior to that demonstrated by sildenafil (Viagra ) in diabetic animal studies.
CF602 has a mechanism of action similar to sildenafil.
this notice of allowance, we believe we now have a broad spectrum of IP coverage which protects a broad spectrum of A3AR ligands
in the treatment of erectile dysfunction. Based on this coverage, we intend to investigate additional compounds to optimize potential
efficacy and safety for this indication," stated Can-Fite CEO Dr. Pnina Fishman
estimates the value of the erectile dysfunction therapeutic market to be approximately $2.6 billion by 2018 with few drugs on
the market which include Viagra, Cialis and Levitra. According to the American Diabetes Association, approximately 30 million
Americans have diabetes mellitus in the U.S. and 35-75% of men with diabetes mellitus suffer from erectile dysfunction.
is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is
highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the
excellent safety profile of the drug. Studies have shown treatment with CF602 results in statistically significant full recovery
from erectile dysfunction after one single dose treatment in a pre-clinical diabetic model. The drug's mechanism of action
includes efficacy in increasing penile intracavernous pressure (ICP) and restoration of impaired vascular endothelial growth factor.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2016 for two indications, rheumatoid
arthritis and psoriasis. The rheumatoid arthritis Phase III protocol has recently been agreed with the European Medicines Agency.
Can-Fite's liver cancer drug CF102 is in Phase II trials for patients with liver cancer and is slated to enter Phase II for the
treatment of non-alcoholic steatohepatitis (NASH). CF102 has been granted Orphan Drug Designation in the U.S. and Europe and Fast
Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. CF102 has
also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third
drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an
IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients
in clinical studies to date. For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other
things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition,
from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities
and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does
not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future
events or otherwise.